Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 4, 2006, Pages 27-30

  Schatzberg, Alan F ^a   Blier, Pierre ^b   Delgado, Pedro L ^c   Fava, Maurizio ^d   Haddad, Peter M ^e   Shelton, Richard C ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE; LITHIUM; NORADRENALIN; PSYCHOTROPIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

BIPOLAR DISORDER; CLINICAL ASSESSMENT; CLINICAL STUDY; CLINICAL TRIAL; CONSENSUS; DATA BASE; DESENSITIZATION; DISCONTINUATION SYNDROME; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SUBSTITUTION; EVIDENCE BASED PRACTICE; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDICAL RESEARCH; NONHUMAN; PATIENT EDUCATION; PATIENT MONITORING; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; RATING SCALE; REVIEW; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; CONSENSUS DEVELOPMENT CONFERENCES; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; PATIENT EDUCATION; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RESEARCH; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; SYNDROME;

EID: 33646762803     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997;58(suppl 7):37-40
2. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998;12:305-313
3. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000;25:255-261
4. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006;67(suppl 4):3-7
5. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000;15:305-318
6. Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002;17:217-225
7. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-368
8. Bogetto F, Bellino S, Revello RB, et al. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002;16:273-283
9. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-1132
10. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001;24:183-197
11. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230-237
12. Haddad PM, Pal BR, Clarke P, et al. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol 2005;19:554-557
13. Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 2006;67(suppl 4):8-13
14. Li Q, Muma NA, Battaglia G, et al. A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. J Pharmacol Exp Ther 1997;282:1581-1590
15. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226
16. El Mansari M, Blier P. Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatry Neurosci 2005;30:268-274
17. Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 1997;58(suppl 7):23-27
18. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997;58:291-297
19. Raap DK, Garcia F, Muma NA, et al. Sustained desensitization of hypothalamic 5-hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(dipropylamino) tetralin in the absence of changes in Gi/o/z proteins. J Pharmacol Exp Ther 1999;288:561-567
20. Rosenstock HA. Sertraline withdrawal in two brothers: a case report. Int Clin Psychopharmacol 1996;11:58-59
21. Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 2006;67(suppl 4):22-26
22. Kellner R. A symptom questionnaire. J Clin Psychiatry 1987;48:268-274
23. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 2006;67(suppl 4):14-21
24. Simon GE, Von Korff M, Rutter CM, et al. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry 2001;58:395-401